MEDTRUVA · PRELAUNCH Preview mode — Ordering opens October 2026 · Join the list for launch pricing Our quality approach →
MedTruva
BODYMAP™ About
RETA-GLP3
RETA-GLP3 - Image 2
RETA-GLP3 - Image 3

RETA-GLP3

Price range: $180.00 through $300.00

Retatrutide (LY3437943) is an investigational triple receptor agonist targeting GIPR, GLP-1R, and GCGR. Available in 30 mg, 40 mg, and 50 mg research formats; strictly for laboratory research and not for human or veterinary use.

99.9% PurityResearch GradeCOA VerifiedThird-Party Tested
View the certificate of analysis for this compound →

Notify me when ordering opens

Ordering opens October 2026. Leave your email and we'll tell you the moment this product is available, with launch pricing.

Research use only. No spam — one email when ordering opens, then you can unsubscribe.

The Purity Guarantee

Verified ≥99% by HPLC & mass spectrometry, third-party tested, with a lot-matched Certificate of Analysis on every vial.

  • Certificate of Analysis available for every lot
  • ≥99% purity, HPLC & mass-spec verified
  • Secure checkout · Free shipping on orders $300+
SKU: N/A Category:

Description

Scientific overview

Retatrutide (LY3437943) is an investigational, single-molecule peptide agonist engineered to activate three nutrient-responsive receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR). These class B G protein-coupled receptors participate in the regulation of pancreatic hormone secretion, appetite signaling, energy balance, and substrate metabolism.

Simultaneous GIPR, GLP-1R, and GCGR agonism is being studied as a strategy to integrate incretin signaling with glucagon-receptor-mediated effects on hepatic metabolism and energy expenditure. Retatrutide has undergone Phase 2 and Phase 3 clinical investigation across obesity and related cardiometabolic conditions; it remains investigational and is not approved for public use as of September 2026.

Research characteristics

  • Molecular class: synthetic, long-acting peptide receptor agonist
  • Primary targets: GIPR, GLP-1R, and GCGR
  • Research focus: nutrient signaling, glucose and lipid metabolism, energy homeostasis, and body-composition biology
  • Available research formats: 30 mg, 40 mg, and 50 mg

Research-use notice: Supplied for laboratory research only. Not for human or veterinary use, diagnosis, treatment, or consumption. No medical or therapeutic claims are made.

Certificate of Analysis

Every Medtruva lot ships with an independent, third-party certificate of analysis covering identity and purity. The certificate for each lot is published here and searchable by lot number.

Sample · Lab verification in progress
CompoundRETA-GLP3
Lot numberAssigned at first production run
Analytical methodsRP-HPLC (purity) · LC-MS (identity)
PurityPending lab verification
Testing laboratoryIndependent third-party laboratory
Report datePending

Sample certificate. Laboratory testing for the launch lots is in progress. The document below is a sample showing the format every Medtruva certificate follows; it will be replaced by the signed lab report for this lot before ordering opens.

View sample certificate (PDF) Look up a lot number →

For laboratory research only. Certificates describe the analytical results of a specific lot and are not a statement of suitability for any use.

Additional information

Vial Size

30 mg, 40 mg, 50 mg

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Related products